Detail
| LncRNA Name | u50535 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, western blot, Luciferase reporter assay, RNA-seq, etc. |
| Sample | Human CRC cell lines (HCT116, HCT8, DLD1, HCT15), CRC tissues. |
| Expression Pattern | up-regulated |
| Function Description | Taken together, these findings suggest that u50535 can promote CRC growth and metastasis and may serve as a potential biomarker in CRC.Higher expression of u50535 obtained worse overall survival than lower expression (n?=?86). As for the luciferase assay of miR-200 interaction with ZEB1, the 3â?²-UTR regions of ZEB1 was cloned into psi-CHECK2 vector (Promega) and the miR200 mimic was purchased from Ribo company. LncRNA-u50535 expression is frequently increased and is associated with poor prognosis of CRC. |
| Pubmed ID | 29970882 |
| Year | 2018 |
| Title | The novel long noncoding RNA u50535 promotes colorectal cancer growth and metastasis by regulating CCL20. |
| External Links |
| Links for u50535 | GenBank HGNC lncrnadb Noncode |
| Links for colorectal cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.